In the trials presented on Thursday at TCT, the everolimus-eluting Xience V stent (EES) proved superior to the paclitaxel-eluting Taxus stent at 2 years. But, as Gregg Stone  discussed here recently, a more formidable comparator for EES are the sirolimus-eluting stents (SES). Two trials presented on Friday demonstrated that EES are comparable in efficacy to…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES). Gregg Stone presented two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure —…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.